Award
NIH Reporter #2037T
CSP #2037T, Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-T)
Recipient
Veterans Health Administration, Boston, MA, United States
Awarded
May 06, 2024
Identifier
2037T
A 7-year VA-funded clinical trial comparing the safety and efficacy of apixaban versus rivaroxaban in atrial fibrillation patients, enrolling about 10,000 veterans.
Description
This study will compare two anticoagulants (apixaban and rivaroxaban) used in the Department of Veterans Affairs to prevent strokes in patients with atrial fibrillation. The trial will enroll about 10,000 VA patients nationally and last about 7 years, collecting data from electronic medical records. The study hypothesizes that apixaban will be superior to rivaroxaban for safety and at least non-inferior for efficacy. It is a phase 4, pragmatic, point of care, parallel group, unblinded randomized trial embedded in VA clinical care.